Loomis Sayles & Co. L P Sells 241,194 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Loomis Sayles & Co. L P lessened its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,671,011 shares of the company's stock after selling 241,194 shares during the period. Loomis Sayles & Co. L P owned 0.50% of Roivant Sciences worth $43,428,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of ROIV. TOMS Capital Investment Management LP bought a new position in Roivant Sciences during the 3rd quarter worth approximately $46,333,000. FMR LLC increased its position in shares of Roivant Sciences by 5.6% during the third quarter. FMR LLC now owns 49,145,056 shares of the company's stock worth $567,134,000 after buying an additional 2,593,910 shares during the period. Vanguard Group Inc. raised its stake in Roivant Sciences by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares during the last quarter. Geode Capital Management LLC raised its stake in Roivant Sciences by 23.2% during the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock worth $89,400,000 after buying an additional 1,460,205 shares during the last quarter. Finally, State Street Corp lifted its holdings in Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after buying an additional 1,118,561 shares during the period. Institutional investors own 64.76% of the company's stock.

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the transaction, the chief operating officer now directly owns 1,127,290 shares of the company's stock, valued at approximately $12,197,277.80. This represents a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of the stock in a transaction on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the purchase, the director now owns 96,650,341 shares of the company's stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 1,395,541 shares of company stock valued at $15,028,538. 7.90% of the stock is owned by insiders.

Remove Ads

Roivant Sciences Price Performance

Shares of NASDAQ ROIV traded down $0.01 during midday trading on Tuesday, reaching $10.09. The company's stock had a trading volume of 2,042,331 shares, compared to its average volume of 5,388,859. The stock has a market capitalization of $7.20 billion, a P/E ratio of -67.03 and a beta of 1.26. The firm has a 50 day moving average price of $10.72 and a 200-day moving average price of $11.38. Roivant Sciences Ltd. has a 12-month low of $9.85 and a 12-month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ROIV. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Roivant Sciences presently has a consensus rating of "Buy" and an average price target of $17.10.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.